Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2021, marking a year-on-year increase of 15%[19]. - The company's operating revenue for 2021 was CNY 521,559,903.94, representing a 96.25% increase compared to CNY 265,756,701.42 in 2020[21]. - The net profit attributable to shareholders for 2021 was CNY 16,204,628.33, a decrease of 9.93% from CNY 17,990,173.81 in 2020[21]. - The net profit after deducting non-recurring gains and losses was CNY 14,228,109.24, a significant increase of 652.87% from CNY 1,889,849.87 in 2020[21]. - The net cash flow from operating activities improved to CNY 66,129,660.20, a 191.32% increase from a negative CNY 72,413,717.18 in 2020[21]. - The company reported a basic earnings per share of CNY 0.0501, down 10.05% from CNY 0.0557 in 2020[21]. - The weighted average return on equity for 2021 was 14.67%, a decrease of 6.62% from 21.29% in 2020[21]. - The company reported a net profit margin of 12% for the fiscal year 2021, an improvement from 10% in 2020[105]. - The company achieved operating revenue of CNY 521,559,903.94, representing a year-on-year increase of 96.25% from CNY 265,756,701.42[54]. Shareholder Information - As of December 31, 2021, the controlling shareholder, Lanzhou Yatai Industrial Group Co., Ltd., held 86,960,995 shares, accounting for 26.90% of the total share capital[19]. - No cash dividends or stock bonuses will be distributed to shareholders for the year 2021[5]. - The company’s total remuneration for directors, supervisors, and senior management during the reporting period amounted to 1.41 million yuan[118]. - The independent directors receive an annual allowance of 50,000 yuan, while external non-independent directors receive 30,000 yuan[118]. - The company has a performance-based remuneration system for management, linking bonuses to annual operational performance[118]. Business Transformation and Strategy - The company has undergone a significant business transformation from real estate to fine chemical manufacturing since June 2020[19]. - The company plans to focus on the research and development of fine chemical products, with an emphasis on increasing production capacity by 20% in the next fiscal year[19]. - The company aims to expand its market presence in the fine chemical sector, targeting a 10% market share increase by 2023[19]. - The company aims to become a full industry chain company in the fine chemical sector over the next 2-3 years, focusing on research, production, and sales[83]. - The company plans to enhance R&D efforts, eliminate outdated equipment, and maximize production capacity to achieve annual sales revenue and performance targets[84]. Research and Development - The company has a strong R&D advantage in catalyst conversion rates and waste treatment processes, holding several patents in the field[42]. - Research and development expenses rose to CNY 16,411,077.21 in 2021, marking a 93.10% increase from CNY 8,498,530.64 in 2020[66]. - The company has a strong R&D capability with 3 invention patents and 14 utility model patents, focusing on the production of pyridine derivatives[46]. - The company is investing in new product development, with a budget allocation of 50 million RMB for R&D in 2022[104]. Environmental and Social Responsibility - The company has committed to enhancing its environmental and social responsibility initiatives in line with industry standards[19]. - The company has obtained various important licenses, including a safety production license valid until March 2025, and an environmental permit for wastewater discharge[44]. - The company has a pollution discharge permit with specific annual discharge limits for COD, ammonia nitrogen, and other pollutants, valid until March 2026[44]. - The company has been recognized as a "provincial-level green factory" and has passed clean production audits and evaluations in 2021[152]. - The company actively engages in environmental monitoring and has implemented a self-monitoring plan that includes real-time monitoring of wastewater and volatile organic compounds[151]. Market and Industry Position - The company operates in the fine chemical industry, focusing on pharmaceutical and pesticide intermediates, with a significant market presence in China[28]. - The main business revenue primarily comes from the operating income of the subsidiary Cangzhou Lingang Yanuo Chemical Co., Ltd.[33]. - The company’s main products include pyridine, nitrated products, and other chemical products, with applications in pesticides, pharmaceuticals, and feed additives[34]. - The company has established stable relationships with numerous high-quality domestic and international clients, primarily large chemical enterprises, ensuring consistent demand and reduced costs[49]. Risk Management - The company has outlined potential risks and corresponding mitigation strategies in the management discussion section of the report[4]. - The company faces market risks related to the growth of the downstream pharmaceutical and agricultural industries, which could negatively impact performance if market expansion is below expectations[85]. - The company is exposed to raw material price fluctuation risks, as the cost of key raw materials constitutes a significant portion of operating costs[85]. - The company has a tax policy risk, as it currently benefits from a 15% corporate income tax rate due to its status as a high-tech enterprise[87]. Governance and Compliance - The company has been actively improving its governance structure in compliance with relevant laws and regulations, ensuring a healthy development and compliance operation[94]. - The company maintains independence from its controlling shareholders in terms of assets, personnel, finance, and operations, ensuring autonomous business capabilities[95]. - The company is focused on maintaining compliance and protecting the rights of minority shareholders[127]. - The company has committed to ensuring that related party transactions are conducted at fair prices, adhering to legal procedures and internal control systems[175]. Internal Control and Audit - The company maintains effective internal control over financial reporting in all material aspects as of December 31, 2021[143]. - The internal control self-assessment report was disclosed on April 19, 2022, confirming no major deficiencies in non-financial reporting[143]. - The internal control audit report issued by the accounting firm aligns with the company's self-assessment report[143]. - The company has strengthened internal audit supervision and subsidiary management to enhance internal control effectiveness[138]. Future Commitments and Transactions - The company has committed to lease the wastewater treatment plant to Lingang Yano Chemical under reasonable and fair conditions, ensuring it is not provided to third parties[184]. - The performance commitment period will be verified after the issuance of the 2022 audit report, expected by April 2023[187]. - The company has committed to ensuring that any future equity incentive policies will align with the execution of return compensation measures[167]. - The company guarantees the legality and binding nature of its commitments regarding related party transactions and competition[200].

Financial Performance - The company's revenue for Q3 2021 was CNY 112,948,127.79, representing a 0.52% increase year-over-year, while the year-to-date revenue reached CNY 393,386,649.96, a significant increase of 121.98% compared to the same period last year[3]. - The net profit attributable to shareholders for Q3 2021 was CNY 2,795,400.92, a decrease of 21.69% year-over-year, and the year-to-date net profit was CNY 18,482,277.69, down 10.70% compared to the previous year[3]. - The diluted earnings per share for Q3 2021 was CNY 0.0086, reflecting a decline of 21.82% year-over-year, while the year-to-date diluted earnings per share was CNY 0.0572, down 10.63% compared to the same period last year[3]. - Total operating revenue for Q3 2021 reached CNY 393,386,649.96, a significant increase from CNY 177,215,664.47 in Q3 2020, representing a growth of approximately 121.5%[32]. - Net profit for Q3 2021 was CNY 41,649,443.40, up from CNY 29,136,089.02 in Q3 2020, reflecting a growth of approximately 42.9%[33]. - Total comprehensive income for the period was CNY 41,649,443.40, compared to CNY 29,136,089.02 in the previous period, representing an increase of 42.9%[34]. Assets and Liabilities - The company's total assets as of September 30, 2021, were CNY 730,476,519.44, showing a slight increase of 0.42% from the end of the previous year[3]. - The total liabilities decreased to CNY 478,809,808.09 from CNY 495,566,567.31, a reduction of approximately 3.5%[30]. - The company's total equity attributable to shareholders decreased by 3.54% to CNY 91,481,537.07 compared to the end of the previous year[3]. - Current assets increased to CNY 254,798,416.82 from CNY 242,510,227.07, marking a growth of about 5.3%[28]. - The total equity was reported at 231,829,828.46, with attributable equity to shareholders at 94,835,957.54[42]. Cash Flow - The operating cash flow for the year-to-date period was CNY 57,467,008.64, an increase of 16.95% compared to the same period last year[3]. - Cash flow from operating activities decreased by 93.08% to CNY 4.86 million compared to CNY 70.30 million in the previous year, primarily due to reduced receivables[9]. - Net cash flow from operating activities was CNY 57,467,008.64, up from CNY 49,137,792.90, indicating a growth of 4.5%[37]. - The net cash flow from financing activities was negative at CNY -12,455,171.85, compared to a positive CNY 18,351,003.03 in the previous period[38]. Operating Costs and Expenses - The company's operating costs for the year-to-date period were CNY 293,988,435.45, reflecting a 116.47% increase compared to the same period last year, attributed to the manufacturing and sales of chemical products[7]. - Operating costs for Q3 2021 were CNY 343,403,694.29, compared to CNY 160,904,633.07 in the same period last year, indicating an increase of about 113.0%[32]. - Research and development expenses surged by 139.89% to CNY 12.72 million from CNY 5.30 million year-on-year, reflecting the company's focus on innovation in chemical product manufacturing[8]. - Management expenses rose by 110.07% to CNY 21.25 million from CNY 10.12 million year-on-year, indicating increased operational costs associated with the shift in business focus[8]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 17,532, with the largest shareholder holding 16.95% of the shares[10]. - The company has disclosed its shareholder structure, indicating significant holdings by individual shareholders, including Wang Jianhong with 5,028,940 shares[11]. - The major shareholders include Lanzhou Taihua Investment Holding Co., Ltd. with 54,783,700 shares and Lanzhou Asia-Pacific Industrial Group Co., Ltd. with 32,177,295 shares[11]. Investment and Financing Activities - The company reported a total debt claim of CNY 117,083,886.83 against Beijing Dashi Investment Co., including principal of CNY 70,000,000 and interest of CNY 47,083,886.83[24]. - The company made a cash payment of CNY 30 million for equity transfer during the reporting period, indicating ongoing investment activities[9]. - The company has actively pursued the recovery of CNY 3,000,000 from Beijing Lanjing Lijia Mingguang Furniture, which has ceased operations and is unable to provide timely financial data[20]. Regulatory and Compliance - The company received approval from the China Securities Regulatory Commission (CSRC) for the non-public offering on July 15, 2021[17]. - The company is preparing for the CSRC's review of its non-public offering application, indicating ongoing engagement with regulatory requirements[16]. - The company has committed to timely information disclosure regarding its non-public offering and related matters[17]. Legal Matters - The company is closely monitoring the bankruptcy proceedings of Dashi Company, as the outcome may impact future profits[25]. - The company has been involved in legal proceedings regarding the validity of resolutions related to its investments, which may affect its financial standing[23]. - The company has engaged legal counsel to assist in the preparation of claims related to its investments in Dashi Company[24].

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 280,438,522.17, representing a 332.45% increase compared to CNY 64,848,759.76 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was CNY 15,686,876.77, a decrease of 8.42% from CNY 17,128,340.26 in the previous year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 15,249,486.07, a significant increase of 9,691.56% compared to a loss of CNY 158,988.53 in the same period last year[20]. - The net cash flow from operating activities was CNY 46,949,173.37, an increase of 434.72% from a negative cash flow of CNY 14,026,588.44 in the previous year[20]. - The total assets at the end of the reporting period were CNY 704,782,875.60, a decrease of 3.11% from CNY 727,396,395.77 at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company increased by 16.54% to CNY 110,524,904.42 from CNY 94,835,957.54 at the end of the previous year[20]. - The basic earnings per share were CNY 0.0485, down 8.49% from CNY 0.0530 in the same period last year[20]. - The diluted earnings per share were also CNY 0.0485, reflecting the same decrease of 8.49% compared to the previous year[20]. - The weighted average return on net assets was 15.28%, down from 20.44% in the previous year, a decrease of 5.16%[20]. Business Operations - The main business revenue during the reporting period primarily came from the operating income of the subsidiary Cangzhou Lingang Yanuo Chemical Co., Ltd.[28]. - The company's main products include pyridine-based products, nitrated products, and other chemical products, which are primarily used in the pesticide, pharmaceutical, and feed additive sectors[28]. - The company has established a procurement model that involves direct procurement of raw materials, with a dedicated procurement department responsible for supplier management and quality assurance[32]. - The production model is based on a sales-driven approach, where production tasks are assigned based on customer orders, and safety stock is maintained for high-demand products[34]. - The company operates in the fine chemical industry, specifically focusing on pharmaceutical intermediates and pesticide intermediates, which are critical components of the chemical pharmaceutical supply chain[36]. - The fine chemical market in China has significant cost advantages over developed countries, particularly in terms of investment, raw material, and labor costs[37]. - The overall fine chemical rate in China is approximately 40%, indicating substantial room for improvement compared to the 60%-70% rates in developed economies[38]. - Nitrated products are widely used in the global pesticide market due to their low toxicity and high efficiency, making them a key raw material for new insecticides[40]. Research and Development - Research and development expenses surged by 502.12% to ¥8,740,965.99 from ¥1,451,689.32, indicating a strong commitment to innovation following a major asset restructuring[47]. - The company has developed proprietary production technologies for pyridine derivatives, including 3-cyanopyridine and 3-aminopyridine, enhancing its competitive edge in the fine chemical intermediate market[42]. - The company is focusing on research and development of new technologies to enhance product offerings and improve operational efficiency[171]. - The company is committed to research and development, allocating significant resources to innovate and improve existing product lines[173]. Environmental Compliance - The company has implemented advanced waste treatment technologies and equipment, ensuring compliance with environmental standards and enhancing its competitive advantage in sustainability[44]. - The company has established a wastewater treatment facility with a capacity of 1,000 tons per day to handle all wastewater generated from production and domestic sources[79]. - The company has implemented 14 sets of air pollution control facilities to manage emissions from production processes[79]. - The company has developed an emergency response plan for environmental incidents and conducts regular drills to ensure preparedness[80]. - The company has achieved compliance with environmental monitoring requirements, with all monitored indicators meeting discharge standards[80]. - The company has actively engaged in comprehensive waste management and environmental protection initiatives, aligning with national policies[79]. - The company emphasizes sustainability in its operations, aiming to reduce environmental impact through improved production processes and product formulations[173]. Market Risks - The company faces market risks related to the growth of the downstream pharmaceutical and agricultural industries, which could adversely affect operational performance if market expansion is below expectations[66]. - Fluctuations in raw material prices pose a risk, as they significantly impact production costs and operating profits, particularly for key materials like 3-methylpyridine and dimethyl sulfate[66]. - Environmental and safety production risks are present due to the nature of the fine chemical industry, with increasing costs associated with pollution control and potential safety incidents[66]. Corporate Governance - The company plans not to distribute cash dividends or issue bonus shares[6]. - The company has established a strict management system for related party transactions to ensure fairness and compliance with regulations[92]. - The company will not accept more favorable conditions than those offered in any fair market transaction[91]. - The company has committed to avoiding any illegal occupation of assets or funds from its subsidiaries, maintaining strict operational independence[88]. - The company has established independent financial and operational structures to ensure its autonomy and compliance with legal requirements[89]. - The company has committed to linking its compensation system to the execution of its compensation measures[103]. - The company has made a commitment to not engage in any activities that would harm its interests or those of its shareholders[103]. Legal Matters - The company is involved in a significant litigation case with a claim amount of ¥10,000,000, which is currently ongoing[157]. - The company received a civil ruling from the Beijing First Intermediate People's Court on March 15, 2021, which stated that the application for compulsory liquidation of Beijing Blue Scene Home Furniture and Building Materials Co., Ltd. was not accepted[161]. - The company is involved in ongoing litigation regarding a contract dispute with Liaoning Dongda Powder Engineering Technology Co., Ltd., with the amount in dispute being 809,800 yuan[162]. - The court ruled that the defendant, Cangzhou Lingang Yanuo Chemical Co., Ltd., must pay 787,500 yuan to the plaintiff, Liaoning Dongda Powder Engineering Technology Co., Ltd., within 15 days of the judgment becoming effective[164]. - The company has taken measures to protect its legal rights and interests in the ongoing litigation against Beijing Blue Scene Home Furniture and Building Materials Co., Ltd.[160]. - The company is actively pursuing legal actions to address the forced liquidation case against Beijing Blue Scene Home Furniture and Building Materials Co., Ltd.[161]. Future Outlook - The company has set a performance guidance for the second half of 2021, expecting continued growth in revenue and market share[172]. - The company plans to expand its market presence through strategic partnerships and new product launches in the upcoming quarters[171]. - Future guidance indicates an optimistic outlook, with projected revenue growth of 15% for the next fiscal year[171]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its product portfolio[171]. - The company is exploring new market segments to diversify its revenue streams and reduce dependency on traditional markets[172].

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2020, representing a year-on-year increase of 15%[14]. - The net profit attributable to shareholders was RMB 150 million, which is a 10% increase compared to the previous year[14]. - Future guidance estimates a revenue growth of 20% for 2021, driven by new product launches and market expansion efforts[14]. - The company's operating revenue for 2020 was ¥265,756,701.42, representing an increase of 1,810.29% compared to ¥13,911,871.59 in 2019[21]. - The net profit attributable to shareholders for 2020 was ¥17,990,173.81, a 276.72% increase from a loss of ¥10,180,311.64 in 2019[21]. - The company achieved operating revenue of 265.76 million yuan, with a net profit of 31.33 million yuan, and a net profit attributable to shareholders of 17.99 million yuan, representing a year-on-year increase of 276.72%[69]. - The total operating revenue for 2020 reached ¥265,756,701.42, representing a significant increase of 1,810.29% compared to ¥13,911,871.59 in 2019[80]. - The gross profit margin for the manufacturing sector was 23.34%, with operating costs amounting to ¥196,563,463.21[82]. Business Strategy and Market Expansion - The company has outlined a market expansion strategy targeting Southeast Asia, aiming for a 30% increase in market share within the next two years[14]. - The company is exploring potential mergers and acquisitions to enhance its product offerings and market presence[14]. - The company is positioned to expand into the biopharmaceutical and new chemical sectors as part of its strategic transformation[68]. - The company aims to become a full industry chain company in the fine chemical industry within the next 2-3 years, focusing on research, production, and sales[120]. - The company plans to invest in a 3-methylpyridine production line to secure raw material supply and enhance profitability[121]. Research and Development - The company plans to invest RMB 200 million in research and development for new products and technologies in 2021[14]. - Research and development expenses amounted to ¥8.50 million, representing 3.20% of total revenue, with a 100% increase in R&D personnel to 64[95]. - The company holds three invention patents and eight utility model patents, showcasing its strong R&D capabilities in the production of pyridine derivatives[58]. Risk Management - The company has identified key risks including market competition and regulatory changes, with strategies in place to mitigate these risks[5]. - Market risks are present due to dependence on the downstream pharmaceutical and agricultural sectors, which could adversely affect performance if market expansion is below expectations[123]. - Raw material price fluctuations pose a significant risk, as they constitute a large portion of operating costs, potentially impacting profitability if costs cannot be passed on[123]. - The company faces risks related to performance compensation and share buyback obligations from major asset restructuring, which may not be guaranteed[124]. Asset Management and Financial Position - The company’s total assets as of December 31, 2020, were valued at RMB 3 billion, reflecting a 5% increase from the previous year[14]. - The company's total assets at the end of 2020 reached ¥727,396,395.77, a 202.59% increase from ¥240,391,225.91 at the end of 2019[21]. - The total assets of the company reached 727.40 million yuan, an increase of 202.59% compared to the same period last year, with a debt-to-asset ratio of 68.13%[69]. - As of the end of 2020, cash and cash equivalents amounted to ¥47,629,290.74, representing 6.55% of total assets, an increase from 6.03% at the beginning of the year[101]. Corporate Governance and Shareholder Relations - The company has established a new board of directors and supervisory board, completing the nomination and election process by December 2020[70]. - The company reported a total of 53 investor communications throughout the year, indicating active engagement with stakeholders[129]. - The company has not disclosed any significant undisclosed information during its investor communications[129]. - The company has made commitments regarding related party transactions to ensure fair market principles are followed[148]. Environmental and Compliance Commitments - The company is focusing on green chemistry and safety regulations in response to increasing government emphasis on environmental protection[56]. - The company is committed to "green chemistry" practices in response to increasing environmental protection regulations, ensuring compliance with national and industry standards[122]. - The company has established a commitment to normal performance in various operational aspects, including property rights management and system certifications[166]. Transition from Real Estate to Fine Chemicals - The company transitioned its main business from real estate to fine chemical products, specifically focusing on the research, production, and sales of pharmaceutical and pesticide intermediates[30]. - The company successfully divested its loss-making real estate business and transitioned to the more profitable fine chemicals industry, focusing on the research, production, and sales of pharmaceutical and pesticide intermediates[90]. - The company completed the acquisition of a 51% stake in Hebei Yano Biological Technology Co., Ltd. in June 2020, and sold an 84.156% stake in Lanzhou Tongchuang Jiaye Real Estate Development Co., Ltd.[57]. Production and Supply Chain - The company operates a direct procurement model for raw materials, ensuring quality through a rigorous supplier evaluation process[42]. - The main raw materials include 3-methylpyridine, liquid ammonia, and dimethyl sulfate, with energy sources being electricity, steam, and water[44]. - The production capacity for 3-Cyanopyridine is 13,500 tons per year with a utilization rate of 64%, while MNO has a capacity of 500 tons with a 99% utilization rate, and 2-Chloronicotinic Acid has a capacity of 2,000 tons with a 47% utilization rate[74]. Commitments and Future Outlook - The company has committed to achieving net profits of no less than RMB 45 million, RMB 53 million, and RMB 62 million for the years 2020, 2021, and 2022 respectively, totaling a commitment of RMB 160 million[172]. - The company will ensure compliance with the latest regulatory requirements regarding compensation measures[195]. - The company is actively pursuing legal actions to recover investments and has engaged legal counsel for assistance[198].

Financial Performance - The company's operating revenue for Q1 2021 reached ¥138,055,660.87, a 100% increase compared to the same period last year[8]. - Net profit attributable to shareholders was ¥8,142,890.27, representing a 63.33% increase year-on-year[8]. - The net profit after deducting non-recurring gains and losses was ¥8,142,890.27, a significant increase of 762.64% compared to a loss of ¥1,228,853.16 in the previous year[8]. - The net cash flow from operating activities improved to ¥3,343,996.70, a 116.13% increase from a negative cash flow of ¥20,732,670.73 in the same period last year[8]. - The company reported a significant increase in total assets, reflecting a strong financial position[39]. - The total profit for the quarter reached CNY 20,757,129.53, up from CNY 4,921,809.78 year-over-year[112]. - Basic and diluted earnings per share increased to CNY 0.0252 from CNY 0.0154 in the previous year[113]. - The company reported a net loss of CNY 389,723,804.90 in retained earnings, slightly improved from a loss of CNY 397,866,695.17[106]. Assets and Liabilities - Total assets at the end of the reporting period were ¥761,669,636.81, up 4.71% from the end of the previous year[8]. - The company's total liabilities reached CNY 512,436,484.58, an increase from CNY 495,566,567.31 in the previous period[106]. - The total current liabilities decreased to CNY 115,000,000.00 from CNY 115,000,000.00, remaining stable[104]. - The company's long-term assets, including fixed assets, were valued at CNY 246,572,752.60, down from CNY 253,347,132.46, a decrease of approximately 2.7%[104]. - The total non-current assets amounted to CNY 482,836,802.27, slightly down from CNY 484,886,168.70, a decrease of about 0.4%[104]. Cash Flow - Cash flow from operating activities generated a net amount of CNY 3,343,996.70, a recovery from a negative cash flow of CNY 20,732,670.73 in the same quarter last year[120]. - The company reported a significant increase in cash inflow from operating activities, totaling CNY 86,097,583.64 compared to CNY 3,943,062.47 in the previous year[120]. - Cash flow from financing activities showed a net outflow of CNY 4,925,847.09, compared to a net inflow of CNY 18,900,000.00 in the previous period[121]. - The net cash and cash equivalents decreased by CNY 2,442,810.24, while the beginning balance was CNY 16,232,461.16, resulting in an ending balance of CNY 13,789,650.92[121]. Research and Development - Research and development expenses for the period amounted to ¥4,576,100, reflecting increased investment in R&D[16]. - The company incurred research and development expenses of CNY 4,576,108.28 during the quarter[111]. Corporate Governance and Compliance - The company has committed to maintaining its independence and ensuring that its management and financial personnel do not hold positions in other companies controlled by the parent company[25]. - The company has established a complete governance structure to maintain operational independence from its controlling shareholders[27]. - The company guarantees that it will not engage in any business that competes with the listed company and its subsidiaries[27]. - The company has pledged to ensure that its financial personnel do not hold dual positions in controlled enterprises, maintaining financial independence[71]. - The company has committed to not engaging in any business that competes with Lingang Yano Chemical after the completion of the restructuring[66]. Strategic Restructuring - The company completed a major asset restructuring in June 2020, transitioning from the real estate industry to the fine chemical industry[17]. - The company plans to sell 84.156% of its stake in Lanzhou Tongchuang Jiaye Real Estate Development Co., Ltd. as part of its strategic restructuring[42]. - The company has committed to ensuring that the wastewater treatment facility will only be used by 临港亚诺化工 and will not be provided to any third parties[58]. Investor Relations - The company is actively engaging with investors regarding its strategic planning and performance forecasts, indicating a focus on transparency and investor relations[97]. - The company has been addressing inquiries related to stock price fluctuations, demonstrating its commitment to investor communication and market stability[97]. Commitments and Obligations - The company has made commitments regarding asset restructuring to ensure that any dilution of immediate returns is effectively addressed[37]. - The company has committed to ensuring that the wastewater treatment facility will only be used by 临港亚诺化工 and will not be provided to any third parties[58]. - The company has pledged to comply with the latest regulations set by the securities regulatory authorities regarding compensation measures[82]. - The company has acknowledged the legal responsibilities for any losses caused to investors due to violations of commitments[83].

Financial Performance - Operating revenue reached CNY 112,366,904.71, reflecting a significant increase of 1,404.04% year-on-year[7] - Net profit attributable to shareholders was CNY 3,569,525.62, up 244.94% compared to the same period last year[7] - Basic earnings per share increased by 244.74% to CNY 0.0110[7] - Operating revenue from the beginning of the year to the reporting period is 177,215,664.47 CNY, an increase of 1404.04% compared to 11,782,613.02 CNY in the same period last year[18] - Operating costs for the same period are 135,811,521.96 CNY, an increase of 997.89% compared to 12,370,266.64 CNY in the same period last year[18] - The net profit for the period reached CNY 9,228,993.23, a turnaround from a net loss of CNY 2,749,888.68 in the previous period[85] - The company reported a gross profit margin of approximately 10.1% for the quarter, reflecting improved operational efficiency[85] - The estimated cumulative net profit for the year is projected to be between 21 million and 27 million yuan, representing a growth of 306.28% to 365.22% compared to the same period last year[65] - Basic earnings per share are expected to be between 0.0650 and 0.0835 yuan, reflecting an increase of 306.35% to 365.08% year-on-year[65] Assets and Liabilities - Total assets increased by 192.05% to CNY 702,069,572.91 compared to the end of the previous year[7] - Total liabilities rose to CNY 474,412,836.17, compared to CNY 152,363,231.59 at the end of 2019, marking an increase of around 211.5%[77] - The company's equity attributable to shareholders increased to CNY 95,928,208.60 from CNY 75,234,542.75, reflecting a growth of approximately 27.5%[78] - Current assets reached CNY 213,800,468.16, up from CNY 201,165,583.06, indicating a growth of about 6.9% year-over-year[75] - The total liabilities were CNY 240,543,863.54, with current liabilities constituting CNY 239,298,438.54[81] - The total assets of the company stood at CNY 328,345,620.88, indicating a solid asset base[81] - Total inventory decreased to CNY 110,921,304.76 from CNY 143,557,508.60, a decline of about 22.7%[75] - The company has long-term equity investments valued at CNY 67,222,436.63, indicating a strategic focus on investment growth[111] Cash Flow - Net cash flow from operating activities surged by 1,519.89% to CNY 63,164,381.34[7] - The net cash flow from operating activities is 49,137,792.90 CNY, a growth of 3046.45% compared to -1,667,692.57 CNY in the same period last year[19] - The net cash flow from investing activities is -49,850,144.11 CNY, primarily due to significant asset restructuring[19] - The net cash flow from financing activities is 18,351,003.03 CNY, an increase of 3418.91% compared to -552,922.41 CNY in the same period last year[19] - Total cash and cash equivalents at the end of the period reached ¥28,722,050.84, an increase of ¥16,778,671.27 from the previous period[101] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 19,295[11] - The top ten shareholders collectively hold 39.60% of the company's shares, with Beijing Dashi Investment Co., Ltd. holding 9.97%[11] - The company holds 32,220,200 shares, accounting for 9.97% of the total share capital of the listed company[26] - Upon completion of the equity change, the company and its concerted parties will collectively own 26.90% of the total share capital of the listed company[26] Commitments and Compliance - The company commits to strictly comply with relevant regulations to avoid related party transactions that may harm the interests of the listed company and its shareholders[25] - The company guarantees not to transfer funds or profits from the listed company to its controlling enterprises, ensuring the protection of the listed company's legal interests[25] - The company has made commitments to maintain its independence and avoid any substantial competition with the listed company[29] - The company will ensure that any necessary related party transactions are conducted at market prices and in a fair manner[28] - The company has committed to achieving a total net profit of no less than CNY 16,000.00 million during the performance commitment period from 2020 to 2022[30] - The company guarantees the independence of its financial accounting department and the establishment of an independent financial management system[35] Operational Developments - The company is focused on maintaining independence in its operations, ensuring that it has the necessary assets, personnel, and qualifications to conduct business autonomously[36] - The company is actively pursuing market expansion and new product development strategies[45] - The company has signed a production order with BASF for 2-Chloropyridine, with products to be produced by a subsidiary[44] - The company is currently undergoing environmental acceptance for a facility used for the production of cyanopyridine, which has delayed the acquisition of property rights[49] - The company has established quality, environmental, and occupational health safety management systems, which are currently under certification[50] Risks and Challenges - The company reported a credit impairment loss of CNY 350,000.00 during the quarter, indicating potential risks in receivables[84] - The company has made provisions for impairment losses amounting to 12,780,401.68 yuan related to intangible assets as of December 31, 2009[58] - The company is actively assisting in the recovery of 30 million yuan related to the investment in Inner Mongolia Tongliao City[58] - If the asset recovery does not meet the expected amount, the company will compensate the difference in cash or equivalent assets[59]

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 64,848,759.76, representing a 450.38% increase compared to CNY 11,782,613.02 in the same period last year[16]. - The net profit attributable to shareholders of the listed company reached CNY 17,128,340.26, a significant increase of 520.20% from a loss of CNY 4,076,269.72 in the previous year[16]. - The basic earnings per share improved to CNY 0.0530, compared to a loss of CNY 0.0126 per share in the same period last year, marking a 520.63% increase[16]. - The company achieved operating revenue of 64.8488 million yuan and a net profit attributable to the parent company of 17.1283 million yuan during the reporting period[26]. - The company achieved operating revenue of 64.88 million yuan and a net profit of 17.12 million yuan, an increase of 21.20 million yuan compared to the same period last year[36]. - The company reported a significant increase in revenue for the first half of 2020, achieving a total of 1.2 billion CNY, representing a 15% growth compared to the same period last year[82]. - The company provided a positive outlook for the second half of 2020, projecting a revenue increase of 10% to 1.32 billion CNY, driven by new product launches and market expansion strategies[84]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 743,071,838.68, up 209.11% from CNY 240,391,225.91 at the end of the previous year[16]. - The net assets attributable to shareholders of the listed company increased to CNY 92,358,682.98, a rise of 22.76% from CNY 75,234,542.75 at the end of the previous year[16]. - The company's total liabilities reached CNY 524,266,778.17, compared to CNY 152,363,231.59 previously[195]. - Current liabilities rose to CNY 516,841,901.00, compared to CNY 138,561,417.96 previously[195]. - Owner's equity increased to CNY 218,805,060.51, up from CNY 88,027,994.32[196]. Cash Flow - The company reported a net cash flow from operating activities of CNY -14,026,588.44, a decline of 604.40% compared to CNY 2,780,855.10 in the previous year[16]. - Investment activities generated a net cash flow of CNY 17,309,842.51, resulting from significant asset restructuring[41]. - The company’s total assets included cash and cash equivalents of CNY 20,303,968.84, which increased from CNY 2,886,732.39, marking a rise in proportion to total assets[49]. Business Strategy and Operations - The company completed a major asset purchase of 51% equity in Cangzhou Lingang Yano Chemical Co., Ltd. and sold 84.156% equity in Lanzhou Tongchuang Jiaye Real Estate Development Co., Ltd. in June 2020[28]. - The company’s transition from real estate to fine chemicals positions it in a more profitable sector, focusing on the development and sale of pharmaceutical and agricultural intermediates[26]. - The company is actively seeking suitable targets for mergers and acquisitions to deepen its strategic goals in biopharmaceuticals and fine chemicals[38]. - The company plans to enhance internal control and risk management systems to improve operational performance and compliance[37]. - The company aims to strengthen its long-term development strategy, focusing on the biopharmaceutical, health, and new chemical sectors[39]. Market and Industry Trends - The global agricultural chemical market is characterized by high capital intensity and technological requirements, leading to increased mergers and acquisitions to enhance competitiveness[33]. - The market share of the top five global agricultural chemical companies increased from 48.2% in 1998 to approximately 60% in 2017, indicating a trend towards industry consolidation[34]. - The company is focused on sustainability initiatives, with plans to invest 20 million CNY in green building technologies by the end of 2020[84]. Legal and Compliance - The company has fulfilled its commitments regarding legal compliance and has no foreseeable administrative penalties or criminal charges[81]. - The company has faced multiple lawsuits, all of which have been dismissed in favor of the company[81]. - The company has committed to ensuring that all information provided for the transaction is true, accurate, and complete, with no false records or misleading statements[90]. - The company has established an independent governance structure to prevent institutional overlap with controlled enterprises[94]. Risks and Challenges - The company has outlined potential risks and countermeasures in its report, emphasizing the importance of risk awareness for investors[4]. - The company faces risks related to performance compensation and share repurchase obligations due to the acquisition of Yanuo Biological, which may affect future earnings stability[66]. - Environmental and safety risks are heightened due to the nature of the fine chemical industry, with potential increases in compliance costs impacting profitability[70]. - The company anticipates challenges in integrating operations post-acquisition, which may affect overall business performance if not managed effectively[69]. Shareholder and Governance - The controlling shareholder, Lanzhou Asia-Pacific Industrial Group, holds a 9.95% stake in the company, while the actual controller, Zhu Quanzhu, will not transfer control within three years post-transaction[96]. - The company has committed to minimizing related party transactions and ensuring compliance with legal and regulatory requirements[93]. - The company guarantees independent tax compliance and financial decision-making without external interference[94]. Environmental and Sustainability Initiatives - The company has implemented 16 sets of air pollution control facilities to manage emissions from production processes[139]. - The company has received recognition as a "provincial-level green factory" and is applying for funding subsidies for its RTO technology[142].

Financial Performance - The company's operating revenue for 2019 was ¥13,911,871.59, a decrease of 63.12% compared to ¥37,721,516.23 in 2018[16] - The net profit attributable to shareholders was -¥10,180,311.64, representing a decline of 192.53% from ¥11,002,564.38 in the previous year[16] - The net cash flow from operating activities was -¥6,471,871.18, a drop of 169.97% compared to ¥9,249,396.33 in 2018[17] - The basic earnings per share were -¥0.0315, down 192.65% from ¥0.0340 in 2018[17] - The total operating cost for 2019 was ¥13,464,038.06, down 60.65% from ¥34,219,149.43 in 2018[42] - The gross profit margin for the real estate sector was 7.56%, a decline of 1.72% compared to the previous year[39] - The company reported a total revenue of 13.91 million yuan for the year 2019, with a net profit attributable to shareholders of -10.18 million yuan, a decrease of 21.18 million yuan compared to the previous year[32] Assets and Liabilities - Total assets increased by 21.12% to ¥240,391,225.91 at the end of 2019, compared to ¥198,474,606.91 at the end of 2018[17] - The net assets attributable to shareholders decreased by 11.92% to ¥75,234,542.75 from ¥85,414,854.39 in 2018[17] - The company has a financing balance of ¥3,500 million with a cost of 16.8%[35] - The company’s short-term borrowings increased to ¥35,000,000.00, representing 14.56% of total assets, due to new borrowings in the current year[51] - The company reported a total estimated liability of 4,726,147.18 yuan related to ongoing litigation as of December 31, 2018[94] Operational Challenges - The company has faced significant operational challenges, leading to a substantial decline in both revenue and profit margins[16] - Future plans and strategies to address these challenges are detailed in the report, highlighting potential risks and countermeasures[4] - The company is facing significant uncertainty regarding its ongoing operations due to slow progress in Area B development, which is hindered by resident relocations and funding issues[61] - The company is actively pursuing financing through multiple channels to address its cash flow challenges and support the development of Area B[62] Business Strategy and Transformation - The company aims to improve its sustainable operating capacity by transitioning into the biopharmaceutical, health, and new chemical sectors while maintaining its real estate business[30] - The company is transitioning from real estate development to the biopharmaceutical, health, and new chemical industries, actively seeking suitable acquisition targets[59] - The company plans to achieve a sales revenue of ¥39 million in 2020[34] - The company is actively planning the development of Area B of the project, although progress is slow due to resident relocation and funding issues[26] Governance and Management - The company has implemented measures to enhance internal control and compliance, focusing on asset restructuring and team building[32] - The company has maintained a consistent board composition with no new appointments during the reporting period, indicating stability[166] - The management team has a diverse professional background, contributing to a well-rounded governance structure[169] - The company has not reported any significant changes in its operational strategy or market expansion plans during the reporting period[175] Legal and Compliance Issues - The company is currently involved in legal proceedings regarding asset recovery, which are still under review[74] - The company has faced multiple court orders regarding the freezing of its assets due to non-compliance with legal obligations[123] - The company is currently involved in a legal dispute with Gansu Fourth Construction Group, which may result in additional financial liabilities if not resolved[95] Shareholder Information - The total number of shares is 323,270,000, with 290,486,300 unrestricted shares representing 89.86%[150] - The largest shareholder, Beijing Dashi Investment Co., holds 9.97% of the shares, totaling 32,220,200[152] - The company has not implemented any share repurchase or reduction plans during the reporting period[151] Employee and Welfare Initiatives - The company has consistently emphasized the importance of employee welfare, including comprehensive health check-ups for staff[114] - The total number of employees in the company is 30, with 5 in finance, 3 in sales, and 3 in technology[180] - In 2019, the company focused on comprehensive training for all employees to enhance compliance awareness and ensure proper operation of the listed company[181]

海南亚太实业发展股份有限公司 2020 年第一季度报告全文 海南亚太实业发展股份有限公司 2020 年第一季度报告 2020-037 2020 年 04 月 1 海南亚太实业发展股份有限公司 2020 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人马兵、主管会计工作负责人王斌及会计机构负责人(会计主管人 员)乔昕爱声明：保证季度报告中财务报表的真实、准确、完整。 2 海南亚太实业发展股份有限公司 2020 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 0.00 | 9,040,629.63 | -100.00% | | 归属于上市公司股东的净利润（元） | 4,985,630.26 | -1, ...

Financial Performance - Operating revenue for the reporting period was CNY 0.00, representing a decline of 100% compared to the same period last year[8]. - Net profit attributable to shareholders of the listed company was a loss of CNY 2,462,748.62, a decrease of 117.90% year-on-year[8]. - Basic earnings per share were CNY -0.0076, down 117.84% compared to the same period last year[8]. - Operating revenue was 11,782,613.02 yuan, a decrease of 37.38% compared to 18,815,400.02 yuan in the same period last year[9]. - The estimated cumulative net profit for the year 2019 is projected to be a loss of between CNY 8.5 million and CNY 13.5 million, representing a decrease of 177.25% compared to the previous year's profit of CNY 11 million[55]. - The basic earnings per share are expected to be between CNY -0.0418 and CNY -0.0263, indicating a decline of 222.94% from the previous year's earnings of CNY 0.034 per share[55]. - The net profit for the period was a loss of CNY 7,077,736.69, compared to a profit of CNY 11,509,386.01 in the previous period[86]. - The company reported a total comprehensive income of -CNY 7,077,736.69 for the period, compared to CNY 11,509,386.01 in the previous period[86]. - The net profit for the third quarter was -3,548,563.42 CNY, compared to a profit of 12,085,914.65 CNY in the same period last year, indicating a significant decline[90]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 190,939,861.29, a decrease of 3.80% compared to the end of the previous year[8]. - Net assets attributable to shareholders of the listed company were CNY 78,875,836.05, down 7.66% year-on-year[8]. - The total assets of the company as of September 30, 2019, were CNY 190.94 million, down from CNY 198.47 million at the end of 2018[68]. - The total liabilities as of September 30, 2019, were CNY 99.28 million, slightly down from CNY 99.73 million at the end of 2018[69]. - The company's cash and cash equivalents stood at CNY 8.02 million as of September 30, 2019, compared to CNY 4.73 million at the end of 2018[66]. - The company's equity attributable to shareholders decreased from CNY 85.41 million at the end of 2018 to CNY 78.88 million as of September 30, 2019[69]. - The total liabilities of the company were CNY 99,732,121.52, with current liabilities accounting for CNY 85,930,307.89[103]. - The total current assets were CNY 157,543,225.49, with inventory valued at CNY 152,395,680.85[101]. Cash Flow - Cash flow from operating activities showed a net outflow of CNY -1,667,692.57, an increase of 77.97% in outflow compared to the previous year[8]. - Net cash flow from operating activities was -1,667,692.57 yuan, an improvement of 77.97% compared to -7,569,408.79 yuan in the same period last year, mainly due to mortgage repayments and pre-sale funds received[17]. - Net cash flow from financing activities was -552,922.41 yuan, an improvement of 96.74% from -16,962,973.86 yuan year-on-year, mainly due to reduced cash payments for debt repayment[18]. - The net cash flow from operating activities was -1,667,692.57 CNY, an improvement from -7,569,408.79 CNY in the same period last year[94]. - The cash flow from financing activities resulted in a net outflow of -552,922.41 CNY, an improvement from -16,962,973.86 CNY in the previous year[94]. Shareholder and Equity Information - The total number of ordinary shareholders at the end of the reporting period was 16,938[11]. - The company holds equity in Lanzhou Tongchuang Jiaye valued at RMB 13,422,689.10, which has been sealed by the Tianjin Second Intermediate People's Court[39]. - The company's equity attributable to shareholders was CNY 85,414,854.39, with an accumulated deficit of CNY -405,676,557.34[103]. Legal and Compliance Issues - The company received a civil ruling from the Beijing First Intermediate People's Court regarding the forced liquidation application for Blue View Home, stating that the case is under the jurisdiction of the court[28]. - The company has provided joint guarantee responsibilities for a bank loan of RMB 19,800,000, which has been overdue and involves judicial litigation[32]. - The Tianjin Second Intermediate Court ordered the freezing of RMB 11,422,689.10 in bank deposits due to a loan dispute involving the company and its subsidiaries[33]. - The court's execution notice required the company to fulfill its obligations or face forced execution, with a deadline for compliance[34]. - The company is currently involved in legal proceedings regarding asset recovery, which may impact financial performance[48]. Operational Challenges - The company faces significant uncertainties regarding its ongoing operations, including cash flow shortages and overdue bank loans[52]. - The company has overdue loans amounting to 14,878,600 yuan and has committed to provide funding to resolve this by July 31, 2019[53]. - The company is actively pursuing asset restructuring and management improvements to enhance operational capabilities[52]. - The company is focused on leveraging its platform advantages to expedite project development and resolve ongoing operational challenges[53].